Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45–56 (2018).

Article  PubMed  Google Scholar 

Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839–852 (2020).

Article  PubMed  Google Scholar 

Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 20, 31–42 (2019).

Article  CAS  PubMed  Google Scholar 

Shah, B. D. et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 398, 491–502 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roddie, C. et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N. Engl. J. Med. 391, 2219–2230 (2024).

Article  CAS  PubMed  Google Scholar 

Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331–1342 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jacobson, C. A. et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 23, 91–103 (2022).

Article  CAS  PubMed  Google Scholar 

Fowler, N. H. et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat. Med. 28, 325–332 (2022).

Article  CAS  PubMed  Google Scholar 

Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021).

Article  CAS  PubMed  Google Scholar 

Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 398, 314–324 (2021).

Article  CAS  PubMed  Google Scholar 

San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335–347 (2023).

Article  CAS  PubMed  Google Scholar 

Siddiqi, T. et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet 402, 641–654 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nastoupil, L. J. et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J. Clin. Oncol. 38, 3119–3128 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Riedell, P. A. et al. Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas. Transpl. Cell Ther. 28, 669–676 (2022).

Article  CAS  Google Scholar 

Jain, T., Olson, T. S. & Locke, F. L. How I treat cytopenias after CAR T-cell therapy. Blood 141, 2460–2469 (2023).

CAS  PubMed  PubMed Central  Google Scholar 

Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625–638 (2019).

Article  CAS  PubMed  Google Scholar 

Yakoub-Agha, I. et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 105, 297–316 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Santomasso, B. D. et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J. Clin. Oncol. 39, 3978–3992 (2021). This review outlines the grading and standard-of-care management for immune-mediated adverse events associated with CAR-T cell therapy.

Article  CAS  PubMed  Google Scholar 

Brudno, J. N. & Kochenderfer, J. N. Current understanding and management of CAR T cell-associated toxicities. Nat. Rev. Clin. Oncol. 21, 501–521 (2024). This recent review summarizes the frequency, the pathophysiology and the management of toxicities associated with current commercial CAR-T cell products, and provides a comparison of the current practice guidelines published by key professional societies and networks.

Article  PubMed  PubMed Central  Google Scholar 

Rejeski, K. et al. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood 142, 865–877 (2023).

Article  CAS  PubMed  Google Scholar 

Hines, M. R. et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant. Cell. Ther. 29, 438–438 (2023).

Article  PubMed Central  Google Scholar 

Schubert, M. L. et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann. Oncol. 32, 34–48 (2021).

Article  CAS  PubMed  Google Scholar 

Morris, E. C., Neelapu, S. S., Giavridis, T. & Sadelain, M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat. Rev. Immunol. 22, 85–96 (2022). This review summarises the pathophysiology of CRS and ICANS after CAR-T cell therapy.

Article  CAS  PubMed  Google Scholar 

Tvedt, T. H. A., Vo, A. K., Bruserud, Ø. & Reikvam, H. Cytokine release syndrome in the immunotherapy of hematological malignancies: the biology behind and possible clinical consequences. J. Clin. Med. 10, 5190 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang, S. et al. Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma. Nat. Commun. 15, 360 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664–679 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li, X., Shao, M., Zeng, X., Qian, P. & Huang, H. Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. Signal. Transduct. Target. Ther. 6, 367 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hay, K. A. et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy. Blood 130, 2295–2306 (2017).

Article  CAS  PubMed  PubMed Central